Purification of cardiac myocytes from human heart biopsies for gene expression analysis.

University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA.
AJP Heart and Circulatory Physiology (Impact Factor: 4.01). 08/2009; 297(3):H1163-9. DOI: 10.1152/ajpheart.00118.2009
Source: PubMed

ABSTRACT The collection of gene expression data from human heart biopsies is important for understanding the cellular mechanisms of arrhythmias and diseases such as cardiac hypertrophy and heart failure. Many clinical and basic research laboratories conduct gene expression analysis using RNA from whole cardiac biopsies. This allows for the analysis of global changes in gene expression in areas of the heart, while eliminating the need for more complex and technically difficult single-cell isolation procedures (such as flow cytometry, laser capture microdissection, etc.) that require expensive equipment and specialized training. The abundance of fibroblasts and other cell types in whole biopsies, however, can complicate gene expression analysis and the interpretation of results. Therefore, we have designed a technique to quickly and easily purify cardiac myocytes from whole cardiac biopsies for RNA extraction. Human heart tissue samples were collected, and our purification method was compared with the standard nonpurification method. Cell imaging using acridine orange staining of the purified sample demonstrated that >98% of total RNA was contained within identifiable cardiac myocytes. Real-time RT-PCR was performed comparing nonpurified and purified samples for the expression of troponin T (myocyte marker), vimentin (fibroblast marker), and alpha-smooth muscle actin (smooth muscle marker). Troponin T expression was significantly increased, and vimentin and alpha-smooth muscle actin were significantly decreased in the purified sample (n = 8; P < 0.05). Extracted RNA was analyzed during each step of the purification, and no significant degradation occurred. These results demonstrate that this isolation method yields a more purified cardiac myocyte RNA sample suitable for downstream applications, such as real-time RT-PCR, and allows for more accurate gene expression changes in cardiac myocytes from heart biopsies.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Vanilloid type transient receptor potential channel (TRPV) could be a potential environmental sensor to multiple stimuli in many types of cells. In this study, we provide the first evidence of functional vanilloid type 4 transient receptor potential channel (TRPV4) in rat cardiac fibroblasts (CFs). Expression of TRPV4 in CFs was analyzed at mRNA and protein level. Function of TRPV4 in CFs was evaluated using a selective TRPV4 agonist, 4alpha-phorbol 12,13-didecanoate (4alphaPDD) while measuring intracellular Ca(2+) concentration ([Ca(2+)](i)) and membrane currents. Analysis of expression of mRNA transcripts of TRPV subfamily revealed that TRPV2 and TRPV4 were expressed in CFs. Significant immunoreactivity to TRPV4 protein was also detected in CFs. When 4alphaPDD was applied to CFs, [Ca(2+)](i) was elevated in a concentration-dependent manner. The elevation of [Ca(2+)](i) was abolished by the removal of external Ca(2+) and by ruthenium red (RuR). 4alphaPDD also activated non-selective cation currents (NSCCs), which were suppressed by RuR. Moreover, pretreatment of CFs with short interference RNA (siRNA) targeting TRPV4 significantly reduced both 4alphaPDD-induced elevation of [Ca(2+)](i) and NSCC. These results provide strong evidence that endogenous TRPV4 functions as an important regulator of [Ca(2+)](i) in CFs.
    Life sciences 10/2009; 85(23-26):808-14. · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute rejection is still a significant barrier to long-term survival of the allograft. Current acute rejection diagnostic methods are not specific enough or are invasive. There have been a number of studies that have explored the blood or the biopsy to discover genomic biomarkers of acute rejection; however, none of the studies to date have used both. We analyzed endomyocardial biopsy tissue and whole blood-derived messenger RNA from 11 acute rejection and 20 nonrejection patients using Affymetrix Human Genome U133 Plus 2.0 chips. We used a novel approach and gained insight into the biology of rejection based on gene expression in the biopsy, and applied this knowledge to the blood analysis to identify novel blood biomarkers. We identified probesets that are differentially expressed between acute rejection and nonrejection patients in the biopsy and blood, and developed three biomarker panels: (1) based on biopsy-only (area under the curve=0.85), (2) based on biopsy-targeted whole blood (area under the curve=0.83), and (3) based on whole blood-only (area under the curve=0.60) analyses. Most of the probesets replicated between biopsy and blood are regulated in opposite direction between the two sources of information. We also observed that the biopsy-targeted blood biomarker discovery approach can improve performance of the biomarker panel. The biomarker panel developed using this targeted approach is able to diagnose acute cardiac allograft rejection almost as well as the biopsy-only based biomarker panel.
    Transplantation 11/2010; 90(12):1388-93. · 3.78 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014